Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Type IV leader peptidase == Another family of signal aspartic endopeptidases was found in bacteria. Bacteria produce a number of protein precursors that undergo post-translational methylation and proteolysis prior to secretion as active proteins. Type IV prepilin leader peptidases are enzymes that mediate this type of post-translational modification. Type IV pilin is a protein found on the surface of Pseudomonas aeruginosa, Neisseria gonorrhoeae and other Gram-negative pathogens. Pilin subunits attach the infecting organism to the surface of host epithelial cells. They are synthesised as prepilin subunits, which differ from mature pilin by virtue of containing a 6-8 residue leader peptide consisting of charged amino acids. Mature type IV pilins also contain a methylated N-terminal phenylalanine residue. The bifunctional enzyme prepilin peptidase (PilD) from Pseudomonas aeruginosa is a key determinant in both type-IV pilus biogenesis and extracellular protein secretion, in its roles as a leader peptidase and methyl transferase (MTase). It is responsible for endopeptidic cleavage of the unique leader peptides that characterise type-IV pilin precursors, as well as proteins with homologous leader sequences that are essential components of the general secretion pathway found in a variety of Gram-negative pathogens. Following removal of the leader peptides, the same enzyme is responsible for the second posttranslational modification that characterises the type-IV pilins and their homologues, namely N-methylation of the newly exposed N-terminal amino acid residue.
Nutritional yeast in particular is naturally low in fat and sodium and a source of protein and vitamins as well as other minerals and cofactors required for growth. Many brands of nutritional yeast and yeast extract spreads, though not all, are fortified with vitamin B12, which is produced separately by bacteria. In 1920, the Fleischmann Yeast Company began to promote yeast cakes in a "Yeast for Health" campaign. They initially emphasized yeast as a source of vitamins, good for skin and digestion. Their later advertising claimed a much broader range of health benefits, and was censured as misleading by the Federal Trade Commission. The fad for yeast cakes lasted until the late 1930s. Yeast cell walls are used as a source of dietary fiber. Specifically, the glucan part is marketed as "yeast β-glucan" and the mannan part is further processed into mannan-oligosaccharide (MOS).
The industry was also affected by disputes about whether grain or blended whisky was worthy of the name, with an adverse decision in North London Police Court in 1905. A Royal Commission on Whisky and other Potable Spirits was appointed in 1906 and reported in 1909 with a victory for the grain distillers and blenders. The industry was further affected by World War I, Prohibition in the United States and later, by the Great Depression; many of the companies closed and never re-opened. Of the 159 distilleries operating in the boom years around 1900, only 15 survived to 1933. During the 1970s there was a new boom in Scotch whisky production that led to an overproduction in the early 1980s. Starting in 1981 whisky distilleries slashed production by a third and kept it low for a decade. During that time many distilleries closed. Banff, Brora, Coleburn, Convalmore, Dallas Dhu, Glen Albyn, Glenesk, Glen Flagler, Glenlochy, Glen Mhor, Glenugie, Glenury, Millburn, North Port, Port Ellen and St Magdalene were mothballed, shut down or demolished. Since the 2010s, Scotch whisky has entered a new phase of growth with new distilleries like Ardnahoe and Borders opening and older distilleries like Brora, Port Ellen and Rosebank reopening.
Sources: en.wikipedia.org
=== Mitochondrial Ca2+ uniporter (MCU) === The mitochondrial calcium uniporter (MCU) is a protein complex located in the inner mitochondrial matrix that functions to take up calcium ions (Ca2+) into the matrix from the cytoplasm. The transport of calcium ions is specifically used in cellular function for regulating energy production in the mitochondria, cytosolic calcium signaling, and cell death. The uniporter becomes activated when cytoplasmic levels of calcium rise above 1 uM. The MCU complex comprises 4 parts: the port-forming subunits, regulatory subunits MICU1 and MICU2, and an auxiliary subunit, EMRE. These subunits work together to regulate the uptake of calcium in the mitochondria. Specifically, the EMRE subunit functions for the transport of calcium, and the MICU subunit functions in tightly regulating the activity of MCU to prevent the overload of calcium concentrations in the cytoplasm. Calcium is fundamental for signaling pathways in cells, as well as for cell death pathways. The function of the mitochondrial uniporter is critical for maintaining cellular homeostasis. The MICU1 and MICU2 subunits are a heterodimer connected by a disulfide bridge. When there are high levels of cytoplasmic calcium, the MICU1-MICU2 heterodimer undergoes a conformational change. The heterodimer subunits have cooperative activation, which means Ca2+ binding to one MICU subunit in the heterodimer induces a conformational change on the other MICU subunits. The uptake of calcium is balanced by the sodium-calcium exchanger.
When danger loomed, all the burgers (citizens) in a district would form a military unit called a commando and elect officers. A full-time official called a Veldkornet maintained muster rolls but had no disciplinary powers. Each man brought his own weapon, usually a hunting rifle, and horse. Those who could not afford a gun were given one by the authorities. The presidents of the Transvaal and Orange Free State simply signed decrees to concentrate within a week, and the commandos could muster between 30,000-40,000 men. Many did not look forward to fighting against fellow Christians and, by and large, fellow Protestants. Many had an overly optimistic sense of what the war would involve, imagining victory could be achieved as fast and easily as in the First Anglo-Boer War. Many, including many generals, had a sense their cause was holy and just, and blessed by God. It rapidly became clear that the Boers presented the British forces with a severe tactical challenge. The Boers presented a mobile and innovative approach to warfare, drawing on their experiences from the First Boer War. The Boers who made up their commandos were farmers who had their working life in the saddle, as farmers and hunters. They depended on the pot, horse and rifle; they were skilled stalkers and marksmen. As hunters, they had learned to fire from cover; from a prone position and to make the first shot count, knowing that if they missed, the game would be long gone or could charge and potentially kill them.
=== In vivo approaches === The first direct evidence for in vivo persistence of intrinsic disorder has been achieved by in-cell NMR upon electroporation of a purified IDP and recovery of cells to an intact state. This was achieved in 2016. In vivo biotinylation was originally used to study which proteins come in the proximity of each other (proximity tagging). It was hypothesized and proven in 2018 that biotinylation favors intrinsically disordered regions as they are more accessible. Although the association between biotinylation and disorder is not absolute, the preference is strongly suggestive of a disordered state in vivo. Because biotinylation status can be checked for a large number of residues at the same time, large-scale biotin "painting" can identify many likely disordered regions at the same time.
Sources: en.wikipedia.org
==== Metabotype informs about treatment outcomes ==== Pharmacometabolomics may be used in a predictive manner to determine the correct course of action in regards to a patient about to undergo some type of drug treatment. This involves determining the metabolic profile of a patient prior to treatment, and correlating metabolic signatures with the outcome of a pharmaceutical treatment course. Analysis of a patient's metabolic profile can reveal factors that may contribute to altered drug metabolism, allowing for predictions of the overall efficacy of a proposed treatment, as well as potential drug toxicity risks that may differ from the general population. This approach has been used to identify novel or previously characterized metabolic biomarkers in patients, which can be used to predict the expected outcome of that patient following treatment with a pharmaceutical compound. One example of the clinical application of pharmacometabolomics are studies that looked to identify a predictive metabolic marker for the treatment of major depressive disorder (MDD)., In a study with antidepressant Sertraline, the Pharmacometabolomics Network illustrated that metabolic profile at baseline of patients with major depression can inform about treatment outcomes. In addition the study illustrated the power of metabolomics for defining response to placebo and compared response to placebo to response to sertraline and showed that several pathways were common to both.
No trade, no cultural exchanges, no political exchanges, no cooperation on anything that resembles common interests." In August 2020, a La Trobe University professor Nick Bisley wrote that the US–China rivalry "will be no Cold War" but rather will "be more complex, harder to manage, and last much longer". He further wrote that comparing the old Cold War to the ongoing rivalry "is a risky endeavour". In September 2020, the UN secretary-general António Guterres warned that the increasing tensions between the US under Trump and China under Xi were leading to "a Great Fracture" which would become costly to the world. CCP general secretary Xi Jinping replied by saying that "China has no intention to fight either a Cold War or a hot one with any country".
=== Theatrical === The film was scheduled to release on 11 January 2020 but in November 2019, the release was preponed to 9 January to get the benefits of the extended holiday weekend because that year's Pongal fell on 15 January. Darbar opened in 7,000 screens worldwide, including 4,000 screens in India. On 7 January 2020, the Madras High Court blocked the film's release in Malaysia after its producer failed to pay a debt of ₹23 crore to its distributor. The court later revoked the claim after Lyca Productions showed a bank guarantee of ₹4.9 crores.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.